Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Julphar
Teva
Fuji
Argus Health
Deloitte
Merck
Chubb

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,709,444

« Back to Dashboard

Which drugs does patent 7,709,444 protect, and when does it expire?

Patent 7,709,444 protects ERAXIS and is included in one NDA.

This patent has twenty-one patent family members in seventeen countries.
Summary for Patent: 7,709,444
Title:Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Abstract:Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
Inventor(s): Milton; Nathaniel (Indianapolis, IN), Moder; Kenneth Philip (West Lafayette, IN), Sabatowski; James Lawrence (Holland, MI), Sweetana; Stephanie Ann (Bloomington, IN)
Assignee: Pfizer Inc. (New York, NY)
Application Number:11/103,798
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Use;

Drugs Protected by US Patent 7,709,444

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-001 Feb 17, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF FUNGAL INFECTIONS ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin INJECTABLE;IV (INFUSION) 021632-002 Nov 14, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF FUNGAL INFECTIONS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,709,444

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,960,564 Echinocandin pharmaceutical formulations containing micelle-forming surfactants ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,709,444

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 294571 ➤ Try a Free Trial
Australia 3249100 ➤ Try a Free Trial
Australia 776782 ➤ Try a Free Trial
Brazil 0009249 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
QuintilesIMS
Queensland Health
Mallinckrodt
Cerilliant
Colorcon
US Army
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.